Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Constantinidou, Anastasia ^a   Smith, Ian ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Anti HER2 therapy; Chemotherapy free regimen; Early breast cancer; Node negative; Small tumours; Trastuzumab

Indexed keywords

ANASTROZOLE; BIOLOGICAL MARKER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER STAGING; COHORT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MEDICAL AUDIT; METASTASIS POTENTIAL; METHODOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 80054862389     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70316-2     Document Type: Article

References (27)

1. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 Jan 6, 369(9555):29-36.
2. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N EnglJ Med 2006 Feb 23, 354(8):809-820.
3. Spielmann M, Roche H, Delozier T, Canon JL, Romieu G, Bourgeois H, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial J C/in. Oncol 2009 Dec 20, 27(36):6129-6134.
4. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N EnglJ Med 2005 Oct 20, 353(16):1673-1684.
5. Perez EA SV, Davidson NE, et al. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the ncctg N9831 her2-positive adjuvant breast cancer trial. San Antonio Breast Cancer Symposium 2009, abstract 80.
6. Slamon D EW, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC^T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC^TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium 2009, abstract 62.
7. Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. BrJ Cancer 2009 Mar 10, 100(5):680-683.
8. Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pTINOMO breast cancer: a nationwide population-based study. Clin Cancer Res 2003 Mar, 9(3):923-930.
9. Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008 Dec 10, 26(35):5697-5704.
10. Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009 Dec 1, 27(34):5693-5699.
11. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.;. Clin Oncol 2009 Dec l, 27(34):5700-5706.
12. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008 Jun, 19(6):1090-1096.
13. Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, et al. Trastuzumab treatment in tlab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas.;. Clin Oncol 2010 Oct 1, 28(28):e541-e542.
14. McArthur HL MP, Patil S, Howard J, Mahoney K, Conlin AK, et al. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer. ASCO Breast Cancer Symposium 2009, abstract 228.
15. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.;. Clin Oncol 2002 Feb 1, 20(3):719-726.
16. Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005 Apr 1, 23(10):2162-2171.
17. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.; Clin. Oncol 2008 Jun 20, 26(18):2999-3005.
18. Cortes JB, Petrella T., Gelmon IC, Fumoleau P., Verma S., et al. Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2-positive breast cancer. J Clin Oncol 2009, 27(Suppl):15s. (abstract 1022).
19. Baselga J, Gelmon KA, Verma S, Wardley A, Conte R, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.;. Clin Oncol 2010 Mar l, 28(7):1138-1144.
20. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Clin Oncol 2010 Mar 1, 28(7):1124-1130.
21. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.;. Clin Oncol 2009 Nov 20, 27(33):5529-5537.
22. Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.;. Clin Oncol 2009 Nov 20, 27(33):5538-5546.
23. Baselga J BI, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. San Antonio Breast Cancer Symposium 2010, abstract S3-3.
24. Gianni L PT, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumour and safety analysis of a randomized phase II study (NeoSphere). San Antonio Breast Cancer Symposium 2010, abstract S3-2.
25. Knauer M, Cardoso F, Wesseling J, Bedard PL, Linn SC, Rutgers EJ, et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. BrJ Cancer 2010 Dec 7, 103(12):1788-1793.
26. Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of Trastuzumab Without Chemotherapy as a Post-operative Adjuvant Therapy in HER2-positive Elderly Breast Cancer Patients: Randomized Controlled Trial [RESPECT (N-SAS,BC07). Jpn J Clin Oncol 2011 Feb 24.
27. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007 Jul, 18(7):1133-1144.